GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (FRA:6LJ0) » Definitions » Cyclically Adjusted PB Ratio

Matinas BioPharma Holdings (FRA:6LJ0) Cyclically Adjusted PB Ratio : 0.06 (As of Jun. 29, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Matinas BioPharma Holdings Cyclically Adjusted PB Ratio?

As of today (2025-06-29), Matinas BioPharma Holdings's current share price is €2.69. Matinas BioPharma Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €44.85. Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:6LJ0' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.06   Med: 0.93   Max: 3.11
Current: 0.11

During the past years, Matinas BioPharma Holdings's highest Cyclically Adjusted PB Ratio was 3.11. The lowest was 0.06. And the median was 0.93.

FRA:6LJ0's Cyclically Adjusted PB Ratio is ranked better than
88.56% of 682 companies
in the Biotechnology industry
Industry Median: 1.49 vs FRA:6LJ0: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Matinas BioPharma Holdings's adjusted book value per share data for the three months ended in Mar. 2025 was €1.140. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €44.85 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Matinas BioPharma Holdings Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings Cyclically Adjusted PB Ratio Chart

Matinas BioPharma Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.58 1.16 0.06

Matinas BioPharma Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 0.88 0.40 0.06 0.06

Competitive Comparison of Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio falls into.


;
;

Matinas BioPharma Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.69/44.85
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Matinas BioPharma Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Matinas BioPharma Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.14/134.9266*134.9266
=1.140

Current CPI (Mar. 2025) = 134.9266.

Matinas BioPharma Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201506 6.750 100.684 9.046
201509 5.421 100.392 7.286
201512 4.872 99.792 6.587
201603 3.290 100.470 4.418
201606 2.315 101.688 3.072
201609 2.028 101.861 2.686
201612 0.867 101.863 1.148
201703 6.582 102.862 8.634
201706 4.555 103.349 5.947
201709 3.181 104.136 4.122
201712 2.247 104.011 2.915
201803 1.221 105.290 1.565
201806 -0.001 106.317 -0.001
201809 -0.606 106.507 -0.768
201812 2.468 105.998 3.142
201903 10.305 107.251 12.964
201906 9.452 108.070 11.801
201909 9.476 108.329 11.803
201912 8.017 108.420 9.977
202003 16.898 108.902 20.936
202006 15.376 108.767 19.074
202009 13.707 109.815 16.841
202012 12.310 109.897 15.114
202103 12.928 111.754 15.609
202106 12.162 114.631 14.315
202109 11.449 115.734 13.348
202112 10.742 117.630 12.322
202203 9.983 121.301 11.104
202206 9.346 125.017 10.087
202209 8.994 125.227 9.691
202212 7.960 125.222 8.577
202303 7.013 127.348 7.430
202306 5.917 128.729 6.202
202309 4.992 129.860 5.187
202312 4.062 129.419 4.235
202403 3.079 131.776 3.153
202406 3.538 132.554 3.601
202409 2.795 133.029 2.835
202412 1.425 133.157 1.444
202503 1.140 134.927 1.140

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Matinas BioPharma Holdings  (FRA:6LJ0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Matinas BioPharma Holdings Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Matinas BioPharma Holdings Headlines

No Headlines